Plinabulin Combination Trial

BeyondSpring, Inc. (NASDAQ: BYSI) announced an upcoming poster presentation at the 2026 American Society of Clinical Oncology Annual Meeting. The study, known as Study 303, investigates the efficacy and safety of plinabulin in combination with docetaxel and pembrolizumab for patients with metastatic NSCLC who have progressed on PD‑1/PD‑L1 inhibitors. This investigator‑initiated study is supported by Merck and BeyondSpring. The presentation details include a title, presenter/authors, and presentation time/location. Study 303 enrolled 47 patients and evaluates the efficacy and safety of this triple combination as a treatment for patients with metastatic NSCLC after acquired resistance to anti‑PD‑1/L1 inhibitors alone or in chemotherapy combination. The study is registered on ClinicalTrials.gov under NCT05599789. BeyondSpring’s lead asset, Plinabulin, has been studied in over 700 cancer patients and is in late‑stage development across multiple cancer indications. The company’s pipeline focuses on developing first‑in‑class therapies for cancers with high unmet need. The presentation of Study 303 at the ASCO Annual Meeting may provide valuable insights into the potential efficacy of Plinabulin in combination with other treatments for patients with metastatic NSCLC.